Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, a crucial mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Its pipeline of next-generation TYK2 inhibitors includes a potential brain-penetrant candidate for treating multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential topical candidate for immune-mediated dermatologic diseases. It helps patients receive the cure or the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation at a competitive cost.

Sudo Biosciences headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $11.0B in funding across 60 round(s). With a team of 11-50 employees, Sudo Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Sudo Biosciences, raised $30.0M. Discover more about their projects, partnerships, and impact on our platform.